Book a Meeting

Fc Engineered Anti-Human HER2 Therapeutic Antibody, a CDC-Enhanced Biobetter [Lot: CB20-PZ06] (CAT#: Biobet-C006ZP) Datasheet

Whole Humanized Antibody
CDC-Enhanced ado-trastuzumabemtansine is a Fc-modified anti-HER2 therapeutic biobetter antibody. Creative Biolabs' advanced CDC-enhanced antibody platform allows for the production of Fc engineered therapeutic CDC⁺ antibodies. By mutating key amino acids of the Fc region of ado-trastuzumabemtansine, ado-trastuzumabemtansine exhibits a greater binding capacity to C1q, thereby achieving enhanced CDC activity.
HER2-positive breast cancer; metastatic breast cancer; Refractory, metastatic Non small cell lung cancer
Therapeutic antibody; Therapeutic antibody-drug conjugat; biobetter
Not Available

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced ado-trastuzumab emtansine. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
Full Name
erb-b2 receptor tyrosine kinase 2
This gene encodes a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. This protein has no ligand binding domain of its own and therefore cannot bind growth factors. However, it does bind tightly to other ligand-bound EGF receptor family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways, such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. Allelic variations at amino acid positions 654 and 655 of isoform a (positions 624 and 625 of isoform b) have been reported, with the most common allele, Ile654/Ile655, shown here. Amplification and/or overexpression of this gene has been reported in numerous cancers, including breast and ovarian tumors. Alternative splicing results in several additional transcript variants, some encoding different isoforms and others that have not been fully characterized.
Alternative Names
NEU; NGL; HER2; TKR1; CD340; HER-2; MLN 19; HER-2/neu
Gene ID
UniProt ID
Trade name
Approved, Investigational
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Accession Number
CAS number
Antibody Isotype
Whole Humanized Antibody
Trastuzumab emtansine is an antibody drug conjugate (ADC) consisting of the humanized monoclonal antibody trastuzumab (Herceptin) covalently linked to the cytotoxic agent DM1. The United States Food and Drug Administration (FDA) approved trastuzumab emtansine for female patients with trastuzumab-resistant advanced HER2 positive breast cancer on February 22, 2013.
HER2-positive breast cancer; metastatic breast cancer; Refractory, metastatic Non small cell lung cancer
Ado-trastuzumab emtansine
Trastuzumab emtansine

Trastuzumab Emtansine is a HER2 antibody drug conjugate. The antibody part is humanized anti-HER2 IgG1 trastuzumab, and the drug part is DM1, which is a maytansin derivative that inhibits microtubules. Emtansine is a generic name for 4- [N-maleimidomethyl] cyclohexane-1-carboxylic acid ester (MCC) covalently linking linker and DM1, which is produced through chemical synthesis. Trastuzumab Emtansine binds to subdomain IV of the HER2 receptor and enters the cell through receptor-mediated endocytosis. DM1 binds to tubulin in microtubules and inhibits microtubule function, resulting in cell arrest and apoptosis. Similarly, similar to trastuzumab, in vitro antibody-dependent cytotoxicity and inhibition of HER2 receptor signaling are mediated by the antibody portion of trastuzumab emtansine.

It is suitable for treating early HER2-positive early breast cancer or metastatic breast cancer that substantially overexpresses HER2. Approved for gastric cancer, metastatic gastroesophageal junction adenocarcinoma, and metastatic adenocarcinoma of the gastro-esophageal junction, provided that these cancers overexpress HER2.

All products and services are for Research Use Only. Do Not use in humans.


Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *